What is ALEC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.23B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ALEC?

P/E (TTM) is n/a and 52-week range is $1.09 to $3.40 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ALEC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ALEC?

The company profile lists revenue (TTM) near $14M, net income (TTM) near $-11.76B, EPS (TTM) near $-1.09 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Alector Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 111M shares outstanding, ISIN US0144421072 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Alector Inc

$ALEC

Health Care · Biotechnology

IR Run Scenarios

$2.08

+2.97%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 103 full-time employees. The company went IPO on 2019-02-07. The firm is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. The company also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

Employees

103

Website

alector.com

IPO

2019-02-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)